Senda Biosciences

Senda Biosciences

Edit info

  • Founded: 2016
  • Location: Cambridge, MA
  • Employee range: 50 - 200
  • Clinical stage: RD
  • Therapy area: Infectious diseases
  • Drug types: INF, ONC, IMM, GEN
  • Lead product: Undisclosed
  • Funding: $123M C Aug 2022; $98M B Jun 2021
  • Investors: Flagship Pioneering, Samsung Life Science Fund, Qatar Investment Authority, Bluwave Capital and Stage 1 Ventures, Alexandria Venture Investments, Longevity Vision Fund, Mayo Clinic, Partners Investment, State of Michigan Retirement System


sendabiosciences.com

linkedin.com

job board


Drug notes:

Undisclosed programs RD immuno-oncology, metabolic conditions, autoimmune conditions, genetic diseases

About:

Senda Biosciences is pursuing ‘intersystems’ biology to develop medicines. A grand vision in biology is to be able to program any cell in vivo, anywhere in the body, for any function. While many companies are developing methods to program _within the cell_, Senda is also trying to program _to the cell_. Programming to the cell involves understanding the molecule exchange between human and non-human cells that transfer information. Senda is using its ‘Senda Atlas’ platform to deconstruct nature’s code to program “information molecules” and natural nanoparticles with desired bioproperties. Information molecules include mRNA (SendRNA) , DNA, siRNA and gene editors and will enable Senda to target a wide range of currently unreachable cells and tissues in the body.

Jobs:

Senda Biosciences
Head of Analytical Sciences
Cambridge |1 day ago
Apply
Senda Biosciences
Scientist I/II, Nanoparticle Formulations
Cambridge |31 days ago
Senda Biosciences
Senior Manager, Regulatory Affairs
Cambridge |58 days ago
Senda Biosciences
Scientist I/II, Integrative Biology (in vitro)
Cambridge |100+ days ago
Senda Biosciences
Deep Learning AI Lead (Director)
Cambridge |100+ days ago


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com